KR20140008303A - 안구 혈관 질환의 치료를 위한 투여 요법 - Google Patents

안구 혈관 질환의 치료를 위한 투여 요법 Download PDF

Info

Publication number
KR20140008303A
KR20140008303A KR1020137010744A KR20137010744A KR20140008303A KR 20140008303 A KR20140008303 A KR 20140008303A KR 1020137010744 A KR1020137010744 A KR 1020137010744A KR 20137010744 A KR20137010744 A KR 20137010744A KR 20140008303 A KR20140008303 A KR 20140008303A
Authority
KR
South Korea
Prior art keywords
vegf
days
administered
inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137010744A
Other languages
English (en)
Korean (ko)
Inventor
미첼 브리겔
페터 엔드
비나야크 호사그라하라
브루스 자페
에릭 메레디스
로날드 뉴톤
스테판 푸어
위빈 추
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140008303A publication Critical patent/KR20140008303A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137010744A 2010-10-27 2011-10-25 안구 혈관 질환의 치료를 위한 투여 요법 Withdrawn KR20140008303A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40721810P 2010-10-27 2010-10-27
US61/407,218 2010-10-27
PCT/EP2011/068682 WO2012055884A1 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Publications (1)

Publication Number Publication Date
KR20140008303A true KR20140008303A (ko) 2014-01-21

Family

ID=44913251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010744A Withdrawn KR20140008303A (ko) 2010-10-27 2011-10-25 안구 혈관 질환의 치료를 위한 투여 요법

Country Status (12)

Country Link
US (1) US20130197016A1 (enExample)
EP (1) EP2632458B1 (enExample)
JP (1) JP5934229B2 (enExample)
KR (1) KR20140008303A (enExample)
CN (1) CN103167873A (enExample)
AU (1) AU2011322597B2 (enExample)
BR (1) BR112013009701A2 (enExample)
CA (1) CA2814439A1 (enExample)
EA (1) EA022873B1 (enExample)
ES (1) ES2547145T3 (enExample)
MX (1) MX2013004782A (enExample)
WO (1) WO2012055884A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9353122B2 (en) * 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10174006B2 (en) 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
EP3570093B1 (en) 2013-11-15 2021-09-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
JPWO2015147204A1 (ja) * 2014-03-27 2017-04-13 国立大学法人京都大学 血管新生増殖因子を阻害する医薬組成物
CN107206119B (zh) 2014-12-09 2021-01-29 实体科学公司 具有生物相容性层的医疗设备涂层
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP2380572A1 (en) 2005-11-29 2011-10-26 Glaxosmithkline LLC Cancer treatment method
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Also Published As

Publication number Publication date
BR112013009701A2 (pt) 2016-07-19
EP2632458A1 (en) 2013-09-04
JP2013540791A (ja) 2013-11-07
US20130197016A1 (en) 2013-08-01
JP5934229B2 (ja) 2016-06-15
AU2011322597A1 (en) 2013-05-02
EA022873B1 (ru) 2016-03-31
AU2011322597B2 (en) 2015-09-10
EP2632458B1 (en) 2015-08-12
MX2013004782A (es) 2013-06-03
WO2012055884A1 (en) 2012-05-03
CN103167873A (zh) 2013-06-19
ES2547145T3 (es) 2015-10-02
CA2814439A1 (en) 2012-05-03
EA201390618A1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
EP2632458B1 (en) Dosing regimes for the treatment of ocular vascular disease
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2008505173A (ja) 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物
US20240366578A1 (en) Treatment of pain and vasoconstriction
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
TWI535441B (zh) 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成
US20130012531A1 (en) Treatment method
US20110130388A1 (en) Prophylactic or therapeutic agent for axial myopia
JP2013515739A (ja) 血管形成関連の眼疾患の処置のための組成物および方法
WO2012105610A1 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CN118119390A (zh) 用于延长释放克罗卡林疗法的组合物和方法
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
JP2011144111A (ja) 軸性近視の予防または治療剤
JP7267326B2 (ja) 成熟脳損傷の治療における使用のためのｍＧｌｕＲ５のネガティブアロステリックモジュレーター
KR20150051493A (ko) 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관신생 관련 질환의 예방 또는 치료용 약학적 조성물
US9095591B2 (en) Pharmaceutical composition for use in the treatment of glaucoma
EP1708691A1 (en) Combination of organic compounds
JP2002154985A (ja) 眼疾患治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130426

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid